AIM: To investigate the changing pattern of alpha-catenin expression and its relationship to clinical and pathological features of colorectal cancer (CRC) patients. METHODS: Archival tumor samples were analyzed using immunohistochemistry (IHC) for alpha-catenin in 91 patients with advanced CRC. RESULTS: The values of alpha-catenin membrane index (MI) and cytoplasmic index (CI) were significantly related to the depth of tumor invasion (P = 0.027, P = 0.020, respectively), high indices being associated with increased depth of the primary tumor invasion (T3 and T4). Similarly, patients with high alpha-catenin expression had a significantly increased risk of lymph node metastasis (32/39 vs 37/52 for MI and 37/45 vs 32/46 for CI) (P = 0.001, P = 0.0001, respectively, for LNN status). An altered expression (i.e., cytoplasmic pattern) was also related (P = 0.047) to the response to chemotherapy; patients with low CI were more responsive (CR: 7/46) than patients with high CI values (CR: 0/45). There was a marginal effect on survival in patients time with metastases (SWM) (P = 0.087); patients with low CI showing slightly longer SWM, but no such effect on disease free survival (DFS) or disease specific survival (DSS). As to co-expression with another member of the adhesion complex (beta-catenin), high alpha-catenin/beta-catenin MI index was of marginal significance in predicting longer DSS (P = 0.063, log-rank). CONCLUSION: The results implicate that high alpha-catenin expression is intimately involved in the key regulatory mechanisms leading to invasive phenotype, lymph node metastases, and progressive disease in CRC.
AIM: To investigate the changing pattern of alpha-catenin expression and its relationship to clinical and pathological features of colorectal cancer (CRC) patients. METHODS: Archival tumor samples were analyzed using immunohistochemistry (IHC) for alpha-catenin in 91 patients with advanced CRC. RESULTS: The values of alpha-catenin membrane index (MI) and cytoplasmic index (CI) were significantly related to the depth of tumor invasion (P = 0.027, P = 0.020, respectively), high indices being associated with increased depth of the primary tumor invasion (T3 and T4). Similarly, patients with high alpha-catenin expression had a significantly increased risk of lymph node metastasis (32/39 vs 37/52 for MI and 37/45 vs 32/46 for CI) (P = 0.001, P = 0.0001, respectively, for LNN status). An altered expression (i.e., cytoplasmic pattern) was also related (P = 0.047) to the response to chemotherapy; patients with low CI were more responsive (CR: 7/46) than patients with high CI values (CR: 0/45). There was a marginal effect on survival in patients time with metastases (SWM) (P = 0.087); patients with low CI showing slightly longer SWM, but no such effect on disease free survival (DFS) or disease specific survival (DSS). As to co-expression with another member of the adhesion complex (beta-catenin), high alpha-catenin/beta-catenin MI index was of marginal significance in predicting longer DSS (P = 0.063, log-rank). CONCLUSION: The results implicate that high alpha-catenin expression is intimately involved in the key regulatory mechanisms leading to invasive phenotype, lymph node metastases, and progressive disease in CRC.
Authors: Stephan E Baldus; Stefan P Mönig; Sandra Huxel; Stephanie Landsberg; Franz-Georg Hanisch; Katja Engelmann; Paul M Schneider; Jürgen Thiele; Arnulf H Hölscher; Hans P Dienes Journal: Clin Cancer Res Date: 2004-04-15 Impact factor: 12.531
Authors: H Shiozaki; K Iihara; H Oka; T Kadowaki; S Matsui; J Gofuku; M Inoue; A Nagafuchi; S Tsukita; T Mori Journal: Am J Pathol Date: 1994-04 Impact factor: 4.307
Authors: Abdelbaset Buhmeida; Ashraf Dallol; Adnan Merdad; Jaudah Al-Maghrabi; Mamdooh A Gari; Muhammad M Abu-Elmagd; Adeel G Chaudhary; Adel M Abuzenadah; Taoufik Nedjadi; Eramah Ermiah; Fatima Al-Thubaity; Mohammed H Al-Qahtani Journal: Tumour Biol Date: 2013-11-19
Authors: Zhihu Ding; Chaomei Shi; Lan Jiang; Tatiana Tolstykh; Hui Cao; Dinesh S Bangari; Susan Ryan; Mikhail Levit; Taiguang Jin; Karl Mamaat; Qunyan Yu; Hui Qu; Joern Hopke; May Cindhuchao; Dietmar Hoffmann; Fangxian Sun; Mike W Helms; Kerstin Jahn-Hofmann; Sabine Scheidler; Liang Schweizer; Douglas D Fang; Jack Pollard; Christopher Winter; Dmitri Wiederschain Journal: Oncotarget Date: 2017-09-28